NCT05149872View on ClinicalTrials.gov

The Breath-2 Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

November 1, 2022

Study Completion Date

April 1, 2023

Conditions
Peripheral Chemosensitivity
Interventions
OTHER

Muscle relaxation

Rocuronium will be used to induce partial paralysis

OTHER

Reversal

Sugamamdex will be used to reverse muscle relaxation

Trial Locations (1)

2333ZA

Leiden Medical University, Leiden

All Listed Sponsors
lead

Leiden University Medical Center

OTHER